[go: up one dir, main page]

AP2014007983A0 - Indole and indazole compounds that activate AMPK - Google Patents

Indole and indazole compounds that activate AMPK

Info

Publication number
AP2014007983A0
AP2014007983A0 AP2014007983A AP2014007983A AP2014007983A0 AP 2014007983 A0 AP2014007983 A0 AP 2014007983A0 AP 2014007983 A AP2014007983 A AP 2014007983A AP 2014007983 A AP2014007983 A AP 2014007983A AP 2014007983 A0 AP2014007983 A0 AP 2014007983A0
Authority
AP
ARIPO
Prior art keywords
indole
indazole compounds
activate ampk
ampk
activate
Prior art date
Application number
AP2014007983A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
David Christopher Ebner
Kevin James Filipski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2014007983A0 publication Critical patent/AP2014007983A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AP2014007983A 2012-04-10 2013-04-01 Indole and indazole compounds that activate AMPK AP2014007983A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261622129P 2012-04-10 2012-04-10
PCT/IB2013/052604 WO2013153479A2 (fr) 2012-04-10 2013-04-01 Composés d'indole et d'indazole qui activent l'ampk

Publications (1)

Publication Number Publication Date
AP2014007983A0 true AP2014007983A0 (en) 2014-10-31

Family

ID=48237173

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007983A AP2014007983A0 (en) 2012-04-10 2013-04-01 Indole and indazole compounds that activate AMPK

Country Status (42)

Country Link
US (2) US8889730B2 (fr)
EP (1) EP2836490B1 (fr)
JP (1) JP6026642B2 (fr)
KR (1) KR20150002782A (fr)
CN (1) CN104245688A (fr)
AP (1) AP2014007983A0 (fr)
AR (1) AR090633A1 (fr)
AU (1) AU2013246552A1 (fr)
CA (1) CA2869692C (fr)
CO (1) CO7091185A2 (fr)
CR (1) CR20140411A (fr)
CU (1) CU20140118A7 (fr)
CY (1) CY1119194T1 (fr)
DK (1) DK2836490T3 (fr)
DO (1) DOP2014000228A (fr)
EA (1) EA028564B1 (fr)
EC (2) ECSP14020545A (fr)
ES (1) ES2637238T3 (fr)
GT (1) GT201400215A (fr)
HK (1) HK1202547A1 (fr)
HR (1) HRP20171028T1 (fr)
HU (1) HUE033096T2 (fr)
IL (1) IL234860A0 (fr)
IN (1) IN2014DN09200A (fr)
LT (1) LT2836490T (fr)
MD (1) MD20140109A2 (fr)
ME (1) ME02729B (fr)
MX (1) MX2014012330A (fr)
NI (1) NI201400121A (fr)
NZ (1) NZ630700A (fr)
PE (1) PE20142294A1 (fr)
PH (1) PH12014502280A1 (fr)
PL (1) PL2836490T3 (fr)
PT (1) PT2836490T (fr)
RS (1) RS56290B1 (fr)
SG (1) SG11201405571SA (fr)
SI (1) SI2836490T1 (fr)
TN (1) TN2014000420A1 (fr)
TW (1) TWI465431B (fr)
UY (1) UY34736A (fr)
WO (2) WO2013153479A2 (fr)
ZA (1) ZA201406792B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
US9745328B2 (en) * 2013-02-04 2017-08-29 Janssen Pharmaceutica Nv Flap modulators
CA2903657A1 (fr) 2013-02-27 2014-09-04 Shionogi & Co., Ltd. Derives d'indole et d'azaindole ayant chacun une activite d'activation d'ampk
CA2905242C (fr) 2013-03-15 2016-11-29 Pfizer Inc. Composes indoliques activant l'ampk
JP6435923B2 (ja) * 2014-03-07 2018-12-12 Jnc株式会社 ジヒドロピラン化合物、液晶組成物および液晶表示素子
WO2016031842A1 (fr) 2014-08-27 2016-03-03 塩野義製薬株式会社 Dérivé d'azaindole ayant un effet d'activation de l'ampk
AU2015328174B2 (en) 2014-10-06 2020-05-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2016092413A1 (fr) * 2014-12-10 2016-06-16 Pfizer Inc. Composés indoliques et indazoliques qui activent l'ampk
EP3224245B1 (fr) * 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Inhibiteurs de nécrose
AU2016280255A1 (en) 2015-06-18 2018-02-08 Cephalon, Inc. 1, 4-substituted piperidine derivatives
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
WO2017011917A1 (fr) * 2015-07-23 2017-01-26 Thrasos Therapeutics Inc. Méthodes de traitement et de prévention de la polykystose rénale (pkd) au moyen de modulateurs et d'activateurs de la protéine kinase activée par l'amp (ampk)
EP3421467A4 (fr) 2016-02-26 2019-08-07 Shionogi & Co., Ltd Dérivé 5-phénylazaindole possédant un effet d'activation de l'ampk
AU2017240685B2 (en) 2016-03-31 2021-08-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2017178845A1 (fr) 2016-04-15 2017-10-19 Cancer Research Technology Limited Composés hétérocycliques à utiliser en tant qu'inhibiteurs de kinases ret
CN115650985B (zh) 2016-04-15 2024-08-02 癌症研究科技有限公司 作为ret激酶抑制剂的杂环化合物
HUE057838T2 (hu) 2016-06-07 2022-06-28 Jacobio Pharmaceuticals Co Ltd SHP2 inhibitorokként hasznos új heterociklusos származékok
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
JOP20190042B1 (ar) 2016-09-30 2021-08-17 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
JOP20190125B1 (ar) 2016-12-09 2022-03-14 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
TWI664175B (zh) 2017-03-23 2019-07-01 大陸商北京加科思新藥研發有限公司 用於作為shp2抑制劑之新穎雜環衍生物
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
EP3634402A1 (fr) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CA3085006A1 (fr) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Procedes pour preparer des modulateurs du regulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
KR102224550B1 (ko) * 2018-04-02 2021-03-09 울산대학교 산학협력단 신규한 에테르 화합물, 및 광 산화환원 촉매를 이용하여 활성화된 알켄 화합물로부터 에테르 화합물을 제조하는 방법
EP3774825A1 (fr) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
CN108572223B (zh) * 2018-04-23 2021-01-26 南京明捷生物医药检测有限公司 一种测定多肽中活性诱导物质的方法
SG11202102684VA (en) * 2018-09-18 2021-04-29 1 Globe Biomedical Co Ltd Treatment for non-alcoholic fatty liver disease
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
CN113347972B (zh) * 2018-12-31 2025-04-29 利兰·斯坦福青年大学托管委员会 治疗线粒体功能障碍的方法和制剂
WO2020201263A1 (fr) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement et la prévention du remodelage cardiaque
CN112441900B (zh) * 2019-09-05 2024-07-23 浙江中科创越药业有限公司 4-联苯乙酸的制备方法
CN111333486A (zh) * 2020-04-08 2020-06-26 南京优氟医药科技有限公司 一种2-甲基-2-（4-氯苯基）-1,3-丙二醇的生产工艺
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
CN111423379B (zh) * 2020-05-21 2021-08-03 湖南科技大学 取代3-吲唑类Mcl-1蛋白抑制剂及制备方法和应用
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
WO2022072397A1 (fr) 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Activateurs d'ampk et procédés d'utilisation associés
WO2025021039A1 (fr) * 2023-07-21 2025-01-30 深圳众格生物科技有限公司 Agoniste d'ampk et son utilisation
WO2025045185A1 (fr) * 2023-08-31 2025-03-06 深圳众格生物科技有限公司 Composé carbamate substitué par aryle ou hétéroaryle, dérivé et utilisation associée

Family Cites Families (281)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965855D1 (en) 1978-09-25 1983-08-18 Farlane Stuart John Mc Pharmaceutical preparations containing a mollusc extract
JP2602037B2 (ja) 1987-10-31 1997-04-23 持田製薬株式会社 １−アシル−２，３−ジヒドロ−４（１ｈ）−キノリノン−４−オキシム誘導体、その製法およびそれらを主成分とする利尿、降圧、抗浮腫および腹水除去用医薬組成物
GB8814277D0 (en) 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
JPH02264757A (ja) 1989-04-06 1990-10-29 Nippon Steel Chem Co Ltd ニトロインドール類の製造方法
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
US5215994A (en) 1990-09-25 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic derivatives
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
WO1993006082A1 (fr) 1991-09-13 1993-04-01 Merck & Co., Inc. Procede de preparation de 1,4-dihyropyridines-4-substitues
DE4136489A1 (de) 1991-11-06 1993-05-13 Bayer Ag Neue diethylentriamin-derivate und deren verwendung zu diagnostischen und therapeutischen zwecken
TW212798B (fr) 1991-11-25 1993-09-11 Takeda Pharm Industry Co Ltd
EP0545478A1 (fr) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Composés hétérocycliques comme tachykinine antagonistes
AU658729B2 (en) 1992-03-27 1995-04-27 Kyoto Pharmaceutical Industries, Ltd. 3-(1H-imidazol-1-ylmethyl)-1H-indole derivatives
JP3229654B2 (ja) 1992-06-05 2001-11-19 ティーディーケイ株式会社 有機ｅｌ素子用化合物および有機ｅｌ素子
US5616537A (en) 1992-07-03 1997-04-01 Kumiai Chemical Industry Co., Ltd. Condensed heterocyclic derivatives and herbicides
GB2271991A (en) 1992-11-02 1994-05-04 Merck Sharp & Dohme N-(2-oxo-1H-1,4-benzodiazepin-3-yl)-ureas
EP0639573A1 (fr) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
US5354763A (en) 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
KR970701182A (ko) 1994-02-10 1997-03-17 스피겔 알렌 제이 벤조다이아제핀 수용체 부위의 작용물질 및 길항물질로서의 5-헤테로아릴인돌 유도체(5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists)
EP0804416A1 (fr) 1994-07-27 1997-11-05 Sankyo Company Limited Composes heterocycliques utiles comme effecteurs allosteriques au niveau des recepteurs muscariniques
FR2723739B1 (fr) 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
JPH08225535A (ja) 1994-11-15 1996-09-03 Dai Ichi Seiyaku Co Ltd インダゾール誘導体
EP0717143A1 (fr) 1994-12-16 1996-06-19 Lignozym GmbH Système à plusieurs composants pour modifier, dégrader ou blanchir la lignine, des matériaux contenant de la lignine ou des produits similaires de même que leur procédé d'utilisation
US6069156A (en) 1995-04-10 2000-05-30 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as cGMP-PDE inhibitors
WO1997010214A1 (fr) 1995-09-14 1997-03-20 Shionogi & Co., Ltd. Nouveaux derives d'acide phenylacetique et compositions medicinales les contenant
EP0914322A1 (fr) 1996-05-27 1999-05-12 Fujisawa Pharmaceutical Co., Ltd. Nouveaux carboxamides d'indolyle et de benzofuranyle utilises comme inhibiteurs de la production d'oxyde nitrique
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5861398A (en) 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
WO1998028292A1 (fr) 1996-12-23 1998-07-02 Smithkline Beecham Corporation Nouveaux composes renfermant de la piperidine
EP0973767A1 (fr) 1997-03-31 2000-01-26 Dupont Pharmaceuticals Company Indazoles d'urees cycliques utiles comme inhibiteurs de vih protease
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
DE69918799D1 (de) 1998-01-14 2004-08-26 Uab Res Foundation Birmingham Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren
CA2260499A1 (fr) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Compositions pharmaceutiques pour le traitement de dommages ischemiques au cerveau
PL343007A1 (en) * 1998-02-25 2001-07-30 Genetics Inst Inhibitors of phospholipase enzymes
EP1077944A1 (fr) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Composes de carboxamide, compositions et methodes d'inhibition de l'activite de type poly(adp-ribose) polymerase (parp)
AU4981199A (en) 1998-07-08 2000-02-01 Gregory N. Beatch Compositions and methods for modulating sexual activity
AU758789B2 (en) 1998-07-15 2003-03-27 Teijin Limited Thiobenzimidazole derivatives
DE19842354A1 (de) 1998-09-16 2000-03-23 Bayer Ag Isothiazolcarbonsäureamide
FR2783520B1 (fr) 1998-09-21 2000-11-10 Oreal Nouveaux 4-hydroxyindoles cationiques, leur utilisation pour la teinture d'oxydation des fibres keratiniques, compositions tinctoriales et procede de teinture
WO2000028993A1 (fr) 1998-11-19 2000-05-25 Nortran Pharmaceuticals, Inc. Ligands de serotonine en tant que composes favorisant l'erection
AR021509A1 (es) 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
CN1105722C (zh) 1999-11-12 2003-04-16 中国科学院上海药物研究所 含氮杂环基的青蒿素衍生物及其制备方法
WO2001090074A2 (fr) 2000-05-22 2001-11-29 Leo Pharma A/S Benzophenones comme inhibiteurs de l'il-1$g(b) et tnf-$g(a)
AU2001275537A1 (en) 2000-06-20 2002-01-02 Wayne State University N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith
JP2002017387A (ja) 2000-07-06 2002-01-22 Mitsubishi Rayon Co Ltd インドール誘導体の製造法
JP2002017386A (ja) 2000-07-06 2002-01-22 Mitsubishi Rayon Co Ltd インドール−３−カルボン酸誘導体の製造法
WO2002018363A2 (fr) 2000-08-29 2002-03-07 Abbott Laboratories Inhibiteurs de la proteine tyrosine phosphatase
DE10046934A1 (de) 2000-09-21 2002-04-18 Consortium Elektrochem Ind Verfahren zur fermentativen Herstellung von nicht-proteinogenen L-Aminosäuren
EP1332141A1 (fr) 2000-10-25 2003-08-06 AstraZeneca AB Derives de quinazoline
KR20030061390A (ko) 2000-11-01 2003-07-18 메르크 파텐트 게엠베하 안구 질환 치료용 조성물 및 방법
AU2002239277A1 (en) 2000-11-20 2002-05-27 Cor Therapeutics, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof
US6387992B1 (en) 2000-11-27 2002-05-14 Ciba Specialty Chemicals Corporation Substituted 5-heteroaryl-2-(2-hydroxyphenyl)-2h-benzotriazole UV absorbers, a process for preparation thereof and compositions stabilized therewith
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
US20040087620A1 (en) 2001-01-18 2004-05-06 Tatsuo Tsuri Terphenyl compounds bearing substituted amino groups
EP1354877A1 (fr) 2001-01-22 2003-10-22 Shionogi & Co., Ltd. Composes hetero-tricycliques comportant des groupes amine substitues
RU2003126913A (ru) 2001-02-02 2005-03-10 Шеринг Корпорейшн (US) 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс
KR20030076716A (ko) 2001-02-28 2003-09-26 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 효능제로서 아실화 피페리딘 유도체
US6951848B2 (en) 2001-03-12 2005-10-04 Millennium Pharmaceuticals, Inc., Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
GB0106586D0 (en) 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
PT1818325E (pt) 2001-04-16 2010-05-12 Schering Corp Ciclobuteno-1,2-dionas 3,4-di-substituídas como ligandos de receptor de quimoquina cxc
EP1403255A4 (fr) 2001-06-12 2005-04-06 Sumitomo Pharma Inhibiteurs de rho kinase
EP1844771A3 (fr) 2001-06-20 2007-11-07 Wyeth Dérives d'acide indole substitue utilises en tant qu'inhibiteurs de l'inhibiteur-1 (PAI-1) de l'activateur plasminogene
JP2004536104A (ja) 2001-07-05 2004-12-02 シナプティック・ファーマスーティカル・コーポレーション Ｍｃｈ選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体
ATE296628T1 (de) 2001-08-01 2005-06-15 Merck Patent Gmbh Integrinhemmer zur behandlung von augenkrankheiten
US7399759B2 (en) 2001-09-03 2008-07-15 Takeda Pharmaceutical Company Limited 1, 3-benzothiazinone derivatives and use thereof
EP1434775A1 (fr) 2001-10-12 2004-07-07 Schering Corporation Composes de maleimide di-substitues en 3,4, antagonistes du recepteur de la cxc-chimiokine
WO2003035005A2 (fr) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: nouvelle classe de ligands cannabimimetiques efficaces
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
MXPA04003954A (es) 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6933316B2 (en) 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
SE0104331D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
JP2003192716A (ja) 2001-12-27 2003-07-09 Mitsui Chemicals Inc オレフィン重合用触媒および該触媒を用いたオレフィンの重合方法
ES2319753T3 (es) 2002-02-21 2009-05-12 Asahi Kasei Pharma Corporation Derivado del acido fenilalcanoico sustituido y utilizacion del mismo.
EP1478437B1 (fr) 2002-02-27 2005-08-31 Pfizer Products Inc. Inhibiteurs de l'acetyl-coa-carboxylase
US7125906B2 (en) 2002-04-03 2006-10-24 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
US7019017B2 (en) 2002-05-14 2006-03-28 Baylor College Of Medicine Small molecule inhibitors of HER2 expression
AU2003239508A1 (en) 2002-05-21 2003-12-12 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
JPWO2004004701A1 (ja) 2002-07-09 2005-11-04 アステラス製薬株式会社 頻尿および尿失禁治療剤
US6972336B2 (en) 2002-07-18 2005-12-06 Novartis Ag N-alkylation of indole derivatives
WO2004014922A1 (fr) 2002-08-10 2004-02-19 Astex Technology Limited Composes 3-(carbonyl) 1h-indazole utilises en tant qu'inhibiteurs de kinases cycline-dependantes (cdk)
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
FR2846656B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
DK1581492T3 (da) 2002-11-28 2008-11-10 Suven Life Sciences Ltd N-arylsulfonyl-3-substituerede indoler med serotoninreceptoraffinitet, fremgangsmåde til fremstilling heraf og en farmaceutisk sammensætning indeholdende disse
AU2003300131A1 (en) 2003-01-06 2004-11-04 Eli Lilly And Company Indole derivatives as ppar modulators
WO2004063155A1 (fr) 2003-01-06 2004-07-29 Eli Lilly And Company Derives heterocycliques fusionnes utilises en tant que modulateurs ppar
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
ITMI20030287A1 (it) 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
CA2514384C (fr) 2003-02-21 2012-04-10 Chiesi Farmaceutici S.P.A. Derives d'acide 1-phenylalcane-carboxylique pour le traitement de maladies neurodegeneratives
JP2004284997A (ja) 2003-03-24 2004-10-14 Taoka Chem Co Ltd 高純度インドールカルボン酸類の製造方法
JP2004284998A (ja) 2003-03-24 2004-10-14 Taoka Chem Co Ltd １−アルキルインドール類の製造方法
WO2004089367A1 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Utilisation pharmaceutique de 1,2,4-triazoles substituees
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
JP2006522744A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
WO2004089380A2 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Utilisation pharmaceutique de 1,2,4-triazoles fusionnes
EP1615697A2 (fr) 2003-04-11 2006-01-18 Novo Nordisk A/S Utilisation pharmaceutique de pyrazolo 1,5-a]pyrimidines substituees
WO2004099192A2 (fr) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Acides carboxyliques substitues par des heterocycles
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
JP2009513513A (ja) 2003-07-04 2009-04-02 グラクソスミスクライン・ソシエタ・ペル・アチオニ Ｏｒｌ−１受容体リガンドとしての置換インドール
WO2005014554A1 (fr) 2003-08-08 2005-02-17 Astex Therapeutics Limited Composes 1h-indazole-3-carboxamide utilises comme modulateurs de la mapkap kinase
WO2005016862A1 (fr) 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Derive d'acide arylalcanoique substitue et son utilisation
EP2468729B1 (fr) 2003-10-15 2013-12-25 Ube Industries, Ltd. Nouveau dérivé d'indazole
JP2005145859A (ja) 2003-11-13 2005-06-09 Nippon Steel Chem Co Ltd 脱水素化方法及び芳香族複素環化合物の製造方法
JP4458819B2 (ja) 2003-11-13 2010-04-28 株式会社リコー アゾ置換インドール化合物及びこれを用いた光記録媒体
PL1697378T3 (pl) 2003-12-22 2008-04-30 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania
US20050234095A1 (en) 2004-03-25 2005-10-20 Wenge Xie Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
WO2005097203A2 (fr) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Conjugues de proteine serique de composes de modulation du canal ionique, utilisations de ces derniers
JP4510500B2 (ja) 2004-04-15 2010-07-21 株式会社リコー アゾ置換インドール化合物及びアゾ金属キレート化合物、並びに光記録媒体
US7632831B2 (en) 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
DE602005015699D1 (de) 2004-05-12 2009-09-10 Pfizer Prod Inc Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
EP1758899A1 (fr) 2004-06-03 2007-03-07 Brandeis University Additions asymetriques de michael et d'aldol utilisant des catalyseurs bifonctionnels a base de cinchonine
KR20070028553A (ko) 2004-06-18 2007-03-12 바이올리폭스 에이비 염증 치료에 유용한 인돌
US20080146616A1 (en) 2004-06-18 2008-06-19 Kristofer Olofsson Indoles Useful in the Treatment of Inflammation
US20080146811A1 (en) 2004-07-23 2008-06-19 Hongfeng Deng Compounds and Methods For Treatment of Thrombosis
PL1781639T3 (pl) 2004-07-28 2012-07-31 Janssen Pharmaceutica Nv Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
NZ588432A (en) 2004-09-17 2012-03-30 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
US20070299114A1 (en) 2004-10-05 2007-12-27 Shionogi & Co., Ltd. Biaryl Derivatives
JP2008516962A (ja) 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
JP2006131519A (ja) 2004-11-04 2006-05-25 Idemitsu Kosan Co Ltd 縮合環含有化合物及びそれを用いた有機エレクトロルミネッセンス素子
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
JPWO2006051937A1 (ja) 2004-11-15 2008-05-29 塩野義製薬株式会社 ヘテロ５員環誘導体
JP2008525464A (ja) 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−７ニコチン性受容体リガンド並びにその製造及び使用
WO2006071095A1 (fr) 2004-12-31 2006-07-06 Sk Chemicals Co., Ltd. Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
FR2882054B1 (fr) 2005-02-17 2007-04-13 Sanofi Aventis Sa Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
KR101048535B1 (ko) 2005-03-30 2011-07-11 주식회사 대웅제약 항진균성 트리아졸 유도체
WO2006110516A1 (fr) 2005-04-11 2006-10-19 Abbott Laboratories Antagonistes de l'acylhydrazide p2x7 et leurs utilisations
CA2605594A1 (fr) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Compose heterocyclique
CN101175488B (zh) 2005-05-17 2012-04-18 萨可德公司 治疗眼病的组合物和方法
WO2006130437A2 (fr) 2005-05-27 2006-12-07 Brandeis University Reactions asymetriques formatrices de liaison carbone-carbone catalysees par des alcaloides quinquina bifonctionnels
WO2006130453A1 (fr) 2005-05-27 2006-12-07 Brandeis University Additions d'aldol asymetrique au moyen de catalyseurs a base d'alcaloide de quinquina bifonctionnels
ES2371774T3 (es) 2005-06-03 2012-01-10 Abbott Laboratories Derivados de ciclobutilamina.
US20090291988A1 (en) 2005-06-14 2009-11-26 Renata Oballa Reversible Inhibitors of Monoamine Oxidase A and B
WO2007002461A1 (fr) 2005-06-23 2007-01-04 Dr. Reddy's Laboratories Ltd. Thiazoles substitués en 3,4 en tant qu'activateurs de l'ampk
RS50821B (sr) 2005-06-27 2010-08-31 Sanofi-Aventis Derivati pirazolopiridina kao inhibitori beta-adrenergičnog receptora kinaze 1
WO2007005785A1 (fr) 2005-07-04 2007-01-11 Dr. Reddy's Laboratories Ltd. Derives de thiazole utiles comme activateurs de l'ampk
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
EP1754483A1 (fr) 2005-08-18 2007-02-21 Merck Sante Utilisation des dérivés de thiénopyridone comme activateurs de l'AMPK et compositions pharmaceutiques les contenant
EP1931632A4 (fr) 2005-08-18 2011-05-11 Microbia Inc Composes indoles utiles
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
EP1948656A2 (fr) 2005-11-03 2008-07-30 Ilypsa, Inc. Composes d'azaindole et leur utilisation en tant qu'inhibiteurs de phospholipases a2
US20070135383A1 (en) 2005-11-03 2007-06-14 Han-Ting Chang Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
AU2006311767A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
CN101316849A (zh) 2005-11-09 2008-12-03 记忆药物公司 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮及其制备和用途
WO2007058504A1 (fr) 2005-11-21 2007-05-24 Lg Life Sciences, Ltd. Nouveaux composes utilises comme agonistes des ppar gamma et des ppar alpha, procede de preparation afferent et composition pharmaceutique les renfermant
CN1978445B (zh) 2005-12-02 2010-09-01 中国科学院上海药物研究所 一种可用作人源腺苷单核苷酸激活蛋白激酶激活剂的化合物及其制备方法和应用
WO2007070826A1 (fr) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Analogues de l'arylpropionamide, de l'arylacrylamide, de l'arylpropynamide ou de l'arylmethyluree en tant qu'inhibiteurs du facteur xia
EP1966141A1 (fr) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Heterocycles a six elements utiles en tant qu inhibiteurs de serine protease
WO2007079173A2 (fr) 2005-12-30 2007-07-12 Emergent Biosolutions Inc. Nouveaux dérivés de 2-hétéroaryloxyphénol au titre d'agents antibactériens
EP1984360B1 (fr) 2006-02-03 2014-01-15 Eli Lilly & Company Composés et procédés pour moduler les récepteurs FX
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JPWO2007114213A1 (ja) 2006-03-30 2009-08-13 旭化成ファーマ株式会社 置換二環式環状誘導体及びその用途
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
CN101426498A (zh) 2006-04-18 2009-05-06 艾博特公司 香草素受体亚型1（vr1）的拮抗剂及其用途
PL2463283T3 (pl) 2006-04-20 2014-10-31 Pfizer Prod Inc Skondensowane fenyloamidowe związki heterocykliczne do zapobiegania i leczenia chorób pośredniczonych przez glukokinazę
MX2008014672A (es) 2006-05-19 2009-03-09 Abbott Lab Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central.
BRPI0712262A2 (pt) 2006-05-24 2012-07-10 Lilly Co Eli agonistas de fxr
RU2008152065A (ru) 2006-06-08 2010-07-20 Убе Индастриз, Лтд (Jp) Новое производное имидазола со спироциклической структурой в боковой цепи
US7812017B2 (en) 2006-07-03 2010-10-12 Biovitrum Ab (Publ.) 4-substituted indole and indoline compounds
FR2903695B1 (fr) 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100826108B1 (ko) 2006-08-04 2008-04-29 한국화학연구원 퓨란-2-카복실산 유도체 및 그의 제조 방법
AU2007281747B2 (en) 2006-08-07 2013-11-07 Ironwood Pharmaceuticals, Inc. Indole compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
JP2008106037A (ja) 2006-09-29 2008-05-08 Osaka Prefecture Univ インドール化合物の製造方法およびインドール化合物
WO2008054748A2 (fr) 2006-10-31 2008-05-08 Arena Pharmaceuticals, Inc. Dérivés d'indazole en tant que modulateurs du récepteur de la sérotonine 5-ht2a utiles pour le traitement des troubles relatifs à celui-ci
KR20090083956A (ko) 2006-11-29 2009-08-04 화이자 프로덕츠 인크. 스피로케톤 아세틸-ＣｏＡ 카르복실라제 억제제
KR20090127867A (ko) 2006-12-05 2009-12-14 네이셔널 치아오 텅 유니버시티 인다졸 화합물
WO2008072850A1 (fr) 2006-12-11 2008-06-19 Amorepacific Corporation Dérivés de triazine ayant une action inhibitrice contre l'acetyl-coa carboxylase
JP2010513231A (ja) 2006-12-14 2010-04-30 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト たんぱく質キナーゼインヒビターとして有用なジヒドロピリジン誘導体
JP2010512800A (ja) 2006-12-18 2010-04-30 アンブルックス，インコーポレイテッド 非天然のアミノ酸およびポリペプチドを含んでいる組成物、これらが関連する方法、ならびにこれらの利用
EA200900798A1 (ru) 2006-12-22 2010-10-29 Новартис Аг Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
ES2627221T3 (es) 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
EP2120952A4 (fr) 2007-01-15 2011-09-21 Us Of America As Represented By The Secretary Of The Army On Behalf Of The U S Army Res Inst Of Infe Composés antiviraux et leurs procédés d'utilisation
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
JP2008179567A (ja) 2007-01-25 2008-08-07 Toray Ind Inc ピラジン誘導体を有効成分とする抗がん剤
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
MX2009008439A (es) 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
JP5107589B2 (ja) 2007-02-13 2012-12-26 旭化成株式会社 インドール誘導体
JP2008208074A (ja) 2007-02-27 2008-09-11 Toray Ind Inc ピラジン誘導体を有効成分とする抗がん剤
JP2008222576A (ja) 2007-03-09 2008-09-25 Japan Enviro Chemicals Ltd インドール化合物の製造方法
WO2008110863A1 (fr) 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Dérivés d'indazole et leur utilisation comme ligands des récepteurs vanilloïdes
WO2008118822A1 (fr) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions et procédés d'inhibition de la voie de jak
WO2008116911A1 (fr) 2007-03-28 2008-10-02 Neurosearch A/S Dérivés de purinyle et leur utilisation en tant que modulateurs des canaux potassiques
KR20080099174A (ko) 2007-05-07 2008-11-12 주식회사 머젠스 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
WO2008150899A1 (fr) 2007-05-29 2008-12-11 Emory University Thérapies combinées pour le traitement du cancer et des maladies inflammatoires
FR2917735B1 (fr) 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
AR067770A1 (es) 2007-08-03 2009-10-21 Betagenon Ab Derivados de tiazol y ditiazol para el tratamiento de diabetes
KR20090016804A (ko) 2007-08-13 2009-02-18 주식회사 티지 바이오텍 신규 벤질에스테르계 화합물 및 이를 유효성분으로함유하는 비만, 당뇨 및 고지혈증의 예방 및 치료용 조성물
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
KR20100067652A (ko) 2007-08-29 2010-06-21 쉐링 코포레이션 치환된 인돌 유도체 및 이의 사용방법
CA2697375A1 (fr) 2007-08-29 2009-03-12 Schering Corporation Derives d'indole substitues en 2 et 3 pour traiter des infections virales
US8415358B2 (en) 2007-09-17 2013-04-09 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
US20090124680A1 (en) 2007-10-31 2009-05-14 Mazence Inc. Use of prodrug composition containing naphthoquinone-based compound for manufacture of medicament for treatment or prevention of diseases involving metabolic syndrome
WO2009064852A1 (fr) 2007-11-16 2009-05-22 Schering Corporation Dérivés d'indole à substitution par aminosulfonyle en position 3 et leurs procédés d'utilisation
ES2552733T3 (es) 2007-11-16 2015-12-01 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
WO2009084695A1 (fr) 2007-12-28 2009-07-09 Carna Biosciences Inc. Dérivé de 2-aminoquinazoline
CN101925748B (zh) 2008-01-31 2013-01-02 国立大学法人横滨国立大学 流体机械
UA106037C2 (uk) 2008-02-04 2014-07-25 Мерк'Юрі Терап'Ютікс, Інк. Модулятори ampk (амф-активованої протеїнкінази)
WO2009115874A2 (fr) 2008-03-17 2009-09-24 Matrix Laboratories Ltd. Nouveaux composés hétérocycliques, compositions pharmaceutiques les contenant et procédés pour leur préparation
JP2011515355A (ja) 2008-03-20 2011-05-19 エフ．ホフマン−ラ ロシュ アーゲー ピロリジニル誘導体およびその使用
WO2009120783A1 (fr) 2008-03-25 2009-10-01 The Johns Hopkins University Inhibiteurs à haute affinité de protéase ns3/4a du virus de l'hépatite c
AU2009228931B2 (en) 2008-03-27 2013-05-23 Janssen Pharmaceutica Nv Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
AU2009235784B2 (en) 2008-04-11 2013-09-19 Merck Patent Gmbh Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
EP2276761B1 (fr) 2008-04-23 2015-07-29 Rigel Pharmaceuticals, Inc. Composés de carboxamide pour le traitement de troubles métaboliques
CN102015676B (zh) 2008-05-05 2014-05-28 默克专利有限公司 作为amp-活化的蛋白激酶(ampk)活化剂的噻吩并吡啶酮衍生物
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
JP2011521940A (ja) 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
DK2285786T3 (da) 2008-06-16 2013-11-04 Merck Patent Gmbh Quinoxalindion-derivater
JP2011524880A (ja) 2008-06-20 2011-09-08 グラクソ グループ リミテッド 化合物
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
US20110190324A1 (en) 2008-07-16 2011-08-04 Edward Leung Methods of treating atherosclerosis
WO2010010186A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
CA2729581A1 (fr) 2008-07-29 2010-02-04 Pfizer Inc. Heteroaryles fluores
WO2010023594A1 (fr) 2008-08-28 2010-03-04 Pfizer Inc. Dérivés de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol
WO2010036910A1 (fr) 2008-09-26 2010-04-01 Yoshikazu Ohta Protection cardiaque par administration d'un activateur de protéine kinase activée par amp
CN102164909A (zh) 2008-09-26 2011-08-24 弗·哈夫曼-拉罗切有限公司 用于治疗hcv的吡啶或吡嗪衍生物
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
MX2011004505A (es) 2008-10-29 2011-05-31 Merck Sharp & Dohme Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos.
CA2741672A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
WO2010056041A2 (fr) 2008-11-13 2010-05-20 주식회사 머젠스 Composition pharmaceutique destinée au traitement et à la prévention d'affections cardiaques résultant d'ischémie ou de reperfusion ischémique
RU2528406C2 (ru) 2008-11-21 2014-09-20 Раквалиа Фарма Инк. Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
US20110237633A1 (en) 2008-12-11 2011-09-29 Bijoy Panicker Small molecule modulators of hepatocyte growth factor (scatter factor) activity
EP2376484B1 (fr) 2008-12-18 2015-04-22 Merck Serono S.A. Dérivés hétérocycliques fusionnés d'oxadiazole pour le traitement de la sclérose en plaques
WO2010073011A2 (fr) 2008-12-23 2010-07-01 Betagenon Ab Composés utiles comme médicaments
AU2009329879A1 (en) 2008-12-23 2011-08-11 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
JP5658688B2 (ja) 2009-01-28 2015-01-28 ライジェル ファーマシューティカルズ， インコーポレイテッド カルボキサミド化合物およびその使用方法
WO2010086613A1 (fr) 2009-01-30 2010-08-05 Betagenon Ab Composés utiles en tant qu'inhibiteurs tel que ampk
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
US20100210682A1 (en) 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
CA2754685A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitues
UA99882C2 (uk) 2009-03-11 2012-10-10 Пфайзер Інк. Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
EP2408780A2 (fr) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3,3.1¨nonanes
US8785651B2 (en) 2009-03-24 2014-07-22 Sumitomo Chemical Company, Limited Method for manufacturing a boronic acid ester compound
DK2607348T3 (da) 2009-03-31 2021-05-25 Renascience Inc Inhibitor af plasminogenaktivatorinhibitor-1
US8927576B2 (en) 2009-04-06 2015-01-06 PTC Therpeutics, Inc. HCV inhibitor and therapeutic agent combinations
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
WO2010128414A1 (fr) 2009-05-08 2010-11-11 Pfizer Inc. Modulateurs du gpr119
KR20120061063A (ko) 2009-06-05 2012-06-12 화이자 인코포레이티드 Ｇｐｒ 119 조절제로서의 ｌ-(피페리딘-4-일)-피라졸 유도체
EA026674B1 (ru) 2009-07-08 2017-05-31 Балтик Био Аб Соединения, применимые в качестве лекарственных средств
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
WO2011014128A1 (fr) 2009-07-30 2011-02-03 National University Of Singapore Inhibiteurs à petite molécule d'isoprénylcystéine carboxyl méthyltranférase avec une activité anticancer potentielle
GB0915892D0 (en) 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
WO2011032320A1 (fr) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Nouveaux dérivés alcényliques d'oxoindole
WO2011069298A1 (fr) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Nouveaux dérivés de cyclopropane indolinone
JP2013047189A (ja) 2009-12-25 2013-03-07 Kyorin Pharmaceutical Co Ltd 新規パラバン酸誘導体及びそれらを有効成分とする医薬
AU2010338280B2 (en) 2009-12-29 2013-08-22 Poxel Thieno [2,3-b] pyridinedione activators of AMPK and therapeutic uses thereof
CA2786314A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux derives benzimidazole cycliques utiles comme agents antidiabetiques
US8796254B2 (en) 2010-03-31 2014-08-05 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
US8344137B2 (en) 2010-04-14 2013-01-01 Hoffman-La Roche Inc. 3,3-dimethyl tetrahydroquinoline derivatives
EP2566868A1 (fr) 2010-05-05 2013-03-13 GlaxoSmithKline LLC Dérivés pyrrolo [3,2-d]pyrimidin-3-yle utilisés comme activateurs de l'ampk
US8592594B2 (en) 2010-07-02 2013-11-26 Hoffmann-La Roche Inc. Tetrahydro-quinoline derivatives
ES2823350T3 (es) 2010-07-29 2021-05-06 Rigel Pharmaceuticals Inc Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
KR101190141B1 (ko) 2010-08-24 2012-10-12 서울대학교산학협력단 Ａｍｐｋ를 활성화시키는 화합물을 함유하는 약학조성물
WO2012027548A1 (fr) 2010-08-25 2012-03-01 The Feinstein Institute For Medical Research Composés et procédés pour la prévention et le traitement de la maladie d'alzheimer et d'autres maladies
JP2013230986A (ja) 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
RU2635662C2 (ru) 2010-09-10 2017-11-15 Сионоги Энд Ко., Лтд. Конденсированное с гетерокольцом имидазольное производное, обладающее активирующим амрк действием
WO2012040499A2 (fr) 2010-09-22 2012-03-29 Surface Logix, Inc. Inhibiteurs métaboliques
US8546427B2 (en) 2010-10-20 2013-10-01 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
US8809369B2 (en) 2011-01-26 2014-08-19 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CN103517896B (zh) 2011-03-07 2016-09-21 葛兰素史密斯克莱有限责任公司 喹啉酮衍生物
EP2683720A1 (fr) 2011-03-07 2014-01-15 GlaxoSmithKline LLC Dérivés de 1h-pyrrolo[3,2-d]pyrimidinedione
HK1199255A1 (en) 2011-08-12 2015-06-26 F. Hoffmann-La Roche Ag Indazole compounds, compositions and methods of use
SI2817302T1 (sl) 2012-02-21 2016-03-31 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A 1H-indazol-3-karboksamidne spojine kot inhibitorji glikogen sintaza-kinaze-3beta

Also Published As

Publication number Publication date
ECSP14026271A (es) 2015-11-30
HRP20171028T1 (hr) 2017-10-06
NI201400121A (es) 2015-03-05
NZ630700A (en) 2015-11-27
WO2013153479A2 (fr) 2013-10-17
PL2836490T3 (pl) 2017-10-31
US8889730B2 (en) 2014-11-18
WO2014140704A1 (fr) 2014-09-18
MD20140109A2 (ro) 2015-02-28
CO7091185A2 (es) 2014-10-21
AR090633A1 (es) 2014-11-26
TW201402547A (zh) 2014-01-16
ME02729B (fr) 2017-10-20
PE20142294A1 (es) 2014-12-27
PH12014502280B1 (en) 2014-12-15
JP6026642B2 (ja) 2016-11-16
PT2836490T (pt) 2017-08-23
ZA201406792B (en) 2016-01-27
DOP2014000228A (es) 2014-11-30
UY34736A (es) 2013-11-29
GT201400215A (es) 2015-10-15
SG11201405571SA (en) 2014-10-30
EP2836490B1 (fr) 2017-06-14
HUE033096T2 (en) 2017-11-28
EP2836490A2 (fr) 2015-02-18
HK1202547A1 (en) 2015-10-02
WO2013153479A3 (fr) 2013-12-05
LT2836490T (lt) 2017-08-10
US20130267493A1 (en) 2013-10-10
ES2637238T3 (es) 2017-10-11
TWI465431B (zh) 2014-12-21
CN104245688A (zh) 2014-12-24
SI2836490T1 (sl) 2017-08-31
CY1119194T1 (el) 2018-02-14
CR20140411A (es) 2014-10-14
US20150038484A1 (en) 2015-02-05
DK2836490T3 (en) 2017-07-31
KR20150002782A (ko) 2015-01-07
AU2013246552A1 (en) 2014-09-25
EA201491592A1 (ru) 2015-03-31
RS56290B1 (sr) 2017-12-29
CU20140118A7 (es) 2014-11-27
ECSP14020545A (es) 2017-07-31
TN2014000420A1 (fr) 2016-03-30
CA2869692C (fr) 2016-08-02
JP2015512931A (ja) 2015-04-30
EA028564B1 (ru) 2017-12-29
CA2869692A1 (fr) 2013-10-17
MX2014012330A (es) 2015-01-12
IL234860A0 (en) 2014-12-31
IN2014DN09200A (fr) 2015-07-10
PH12014502280A1 (en) 2014-12-15

Similar Documents

Publication Publication Date Title
IL234860A0 (en) Indole and indole compounds which activate ampk
EP2838881A4 (fr) Dérivés d'iso-indolone
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
IL236330A0 (en) Characterization of particles
ZA201406579B (en) Tetrahydro-quinazolinone derivates as tank and parp inhibitors
IL243728B (en) rorc2-inhibiting indole derivatives and their uses
GB201317425D0 (en) Bedding system
GB201218512D0 (en) Property managment system
SG11201500119QA (en) Deluge system
EP2885291A4 (fr) Inhibiteurs de vegfr3
EP2837623A4 (fr) Nouveau dérivé indazole substitué en position 1
EP2885292A4 (fr) Inhibiteurs de vegfr3
GB2502122B (en) Amplifier
PL3401475T3 (pl) Zespół okucia
GB201214990D0 (en) Disaster prevention device
GB201217285D0 (en) Indole derivatives
PL2634424T3 (pl) Sposób budowania fundamentu dla konstrukcji podobnej do wieży
GB2494023B (en) Trailer
GB201203879D0 (en) Pack-a-truck trailer
GB2510757B (en) Deluge system
GB2501945B (en) Deluge system
GB2488447B (en) Trailer
GB201322950D0 (en) Transportation device
GB201211372D0 (en) Amplifier circuits
AU5123P (en) Sprilecstar Cordyline banksii